Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention
JACC · 2026-04 · 87 (16) · 2117-2130
DOI: 10.1016/j.jacc.2025.12.024 ↗Kurz gefasst
Äquivalenzstudie in der Zeitschrift JACC, 2026-04. Verfasst von Runlin Gao und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical C…. Hauptthemen laut MEDLINE: Absorbable Implants, Coronary Artery Disease, Drug-Eluting Stents, Everolimus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The novel thin-strut sirolimus-eluting iron bioresorbable scaffold (IBS) demonstrated safety and efficacy in a nonrandomized first-in-human study. OBJECTIVES: The objective of this study was to compare the IBS with contemporary metallic cobalt chromium everolimus-eluting stents (CoCr-EES) in patients with coronary artery disease. METHODS: IRONMAN-II was a prospective, multicenter, single-blinded, noninferiority randomized trial across 36 centers in China. Eligible patients had myocardial ischemia and 1 or 2 de novo target lesions. Patients were randomly assigned (1:1) to IBS or CoCr-EES, with allocation masked. Optical coherence tomography (OCT) was performed in the first 25 participant pairs. Clinical follow-up was scheduled at 1, 6, and 12 months, and annually to 5 years, with angiographic and OCT follow-up at 2 years. The primary endpoint was 2-year angiographic in-segment late lumen loss (LLL). Powered secondary endpoints included target vessel quantitative flow ratio (QFR) and OCT-derived cross-sectional mean flow area. Other secondary endpoints included target lesion failure (cardiac death, target vessel myocardial infarction [MI], or ischemia-driven target vessel revascularization), the patient-oriented composite endpoint (all-cause death, MI, or any revascularization), their individual components, and device thrombosis. RESULTS: Between March 10 and December 13, 2022, 518 patients were randomized to IBS (n = 259) or CoCr-EES (n = 259). At 2 years, lesion-level in-segment LLL was 0.28 (0.52) mm with IBS and 0.23 (0.43) mm with CoCr-EES (difference: 0.08 mm; 95% CI: -0.02 to 0.18; Pnoninferiority = 0.03). Mean QFR was 0.90 (0.13) with IBS and 0.92 (0.09) with CoCr-EES (difference: -0.02; 95% CI: -0.04 to 0; Pnoninferiority = 0.05). Mean OCT flow area was 6.92 (3.48) mm2 with IBS and 6.64 (2.44) mm2 with CoCr-EES (difference: 0.27; 95% CI: -0.09 to 0.63; Pnoninferiority < 0.0001). Two-year target lesion failure occurred in 7.4% of IBS patients and 5.4% of CoCr-EES patients (HR: 1.37; 95% CI: 0.69-2.73; P = 0.37). No significant between-group differences in the rates of patient-oriented composite endpoint, death, or MI were present between the 2 groups. No scaffold thromboses occurred in the IBS group, whereas 1 stent thrombosis occurred with CoCr-EES. Binary restenosis and revascularization rates were higher with IBS, however, most such events were non-ischemia-driven. CONCLUSIONS: In IRONMAN-II, the sirolimus-eluting IBS was noninferior to CoCr-EES for 2-year in-segment LLL, QFR, and OCT-derived flow area. Clinical event rates were also comparable between groups although non-ischemia-driven revascularization rates were higher after IBS. Longer-term follow-up is necessary to demonstrate whether late benefits are realized after complete IBS resorption. (A Clinical Investigation to Evaluate the Safety and Efficacy of IBS in Patients With Coronary Artery Disease; NCT05206084).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Cardiology, Fuwai Yunnan Hospita…
- Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; National Clinical Research Center for Cardiova…
- Department of Cardiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Catheterization Laboratories, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Cardiovascular Research Institute and Department of Cardiology, General Hospital of Northern Theater Command, Shenyang, China.
- Department of Cardiology, General Hospital of Ningxia Medical University, Yinchuan, China.
Zitieren
APA
Gao, R., Song, L., Fu, G., Guan, C., Li, Y., Jia, S., He, Y., Chen, J., Qi, F., Yu, M., Yang, B., Zhang, Y., Zhang, Z., He, S., Chen, Y., Ma, Y., Zhou, Y., Wang, L., Zhao, G., …, & IRONMAN II Investigators (2026). Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention. JACC, 87(16), 2117-2130. https://doi.org/10.1016/j.jacc.2025.12.024
Vancouver
Gao R, Song L, Fu G, Guan C, Li Y, Jia S, et al. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention. JACC. 2026;87(16):2117-2130. doi:10.1016/j.jacc.2025.12.024
BibTeX
@article{Gao2026,
author = {Gao, Runlin and Song, Lei and Fu, Guosheng and Guan, Changdong and Li, Yang and Jia, Shaobin and He, Yong and Chen, Jiyan and Qi, Feng and Yu, Mengyue and Yang, Bo and Zhang, Yaojun and Zhang, Zheng and He, Shenghu and Chen, Yundai and Ma, Yitong and Zhou, Yujie and Wang, Le and Zhao, Guowei and Qian, Juying and Guo, Ning and Sun, Zhongwei and Huang, Yunfei and Li, Wei and Wang, Yang and Ge, Junbo and Han, Yaling and Stone, Gregg W and IRONMAN II Investigators, IRONMAN II Investigators},
title = {Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention},
journal = {JACC},
year = {2026},
volume = {87},
number = {16},
pages = {2117--2130},
doi = {10.1016/j.jacc.2025.12.024}
}
EUVIMED